Search Results

Displaying Results 426-450 of 1264 "'MED'"

Feb 19, 2026, 13:10 ET SMNP Reviews Launches Flex Upgrade to Live Study Group, Expanding Access for Nurse Practitioner Board Prep

for high-stakes test prep in the U.S., offering live and self-paced online courses, private tutoring, self-study materials, and Qbanks for pre-law, pre-med, and medical school students, as well as for residents, practicing physicians, PAs, and NPs via its acquisition of Rosh Review and Sarah Michelle NP

More news about: Blueprint Test Preparation


Feb 19, 2026, 10:00 ET SkinSpirit and AmSpa Partner to Host Exclusive Cadaver Lab Training for Advanced Clinical Education

@SkinSpiritClinicSpa.About the American Med Spa Association (AmSpa)The American Med Spa Association (AmSpa) is the national organization dedicated to supporting and advancing the medical aesthetics industry.

More news about: SkinSpirit


Feb 18, 2026, 14:30 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4.      Winstedt L, et al. Complete Removal of Extracellular

More news about: Hansa Biopharma AB


Feb 18, 2026, 14:28 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4.      Winstedt L, et al. Complete Removal of Extracellular

More news about: Hansa Biopharma AB


Feb 18, 2026, 12:30 ET InventHelp Inventor Develops New Jewelry Making Kit (MBQ-759)

create a new jewelry making kit that would encourage creativity and offer therapeutic value," said an inventor, from Bronx, N.Y., "so I invented the MED HEAD. My design could provide a special keepsake, environmental awareness, or it can be given as a heartfelt gift."

More news about: InventHelp


Feb 18, 2026, 11:43 ET "Took my Neck From Sagging Ugly Skin to Glowing Younger-Looking Skin" -- Beverly Hills MD Rapid-Lift Advanced Neck Serum Reviews Praise Visible Neck Tightening, Lifting & Youthful Firmness

Mexico to hold a Regenerative Medicine License. Continuing their commitment to innovation and beauty, Dr. Layke and Dr. Danielpour debuted their first med spa,

More news about: Beverly Hills MD


Feb 18, 2026, 10:13 ET VIO Med Spa Brings More Glow to the Golden State, Marking California Entry in Modesto

Officially opening its doors in December 2025, VIO Med Spa Modesto marks a milestone for the brandMeet the Trio Behind VIO Med Spa in ModestoVIO Med Spa in Modesto is owned and operated by brothers Bobby and John Ismail alongside longtime

More news about: VIO Med Spa


Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328.5 Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.6 Griffiths CE, Reich

More news about: Eli Lilly and Company


Feb 18, 2026, 06:33 ET SGT Capital Closes Artificial Intelligence Co-Investment Fund

Co-Investment Fund, which was 25% oversubscribed.  This fund strengthens SGT Capital's strategy to invest in market-leading data analytic, cybersecurity and med-tech companies.  The SGT Capital AI Co-Investment Fund builds on SGT Capital's established track record in technology-enabled sectors and reflects growing

More news about: SGT Capital


Feb 18, 2026, 06:19 ET SGT Capital Closes Artificial Intelligence Co-Investment Fund

Co-Investment Fund, which was 25% oversubscribed.  This fund strengthens SGT Capital's strategy to invest in market-leading data analytic, cybersecurity and med-tech companies.  The SGT Capital AI Co-Investment Fund builds on SGT Capital's established track record in technology-enabled sectors and reflects growing

More news about: SGT Capital


Feb 17, 2026, 12:54 ET Lenire zeigt durchgängig positive Ergebnisse für Tinnitus-Patienten in den USA in der zweiten Peer-Review-Real-World-Studie

Retrospektive Übersichtsarbeit zum Nachweis der Wirksamkeit der bimodalen Neuromodulation bei der Tinnitus-Behandlung in einem klinischen Umfeld Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3 

More news about: Neuromod Devices


Feb 17, 2026, 06:45 ET Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result

More news about: Medtronic plc


Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study

E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3

More news about: Neuromod Devices


Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study

E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3

More news about: Neuromod Devices


Feb 17, 2026, 05:30 ET Lenire montre des résultats positifs constants pour les patients américains souffrant d'acouphènes dans une deuxième étude en situation réelle évaluée par des pairs.

Examen rétrospectif des dossiers démontrant l'efficacité de la neuromodulation bimodale pour le traitement des acouphènes dans un cadre clinique Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3

More news about: Neuromod Devices


Feb 17, 2026, 03:00 ET Cognizant skal levere strategiske teknologitjenester til Wallenius Wilhelmsen

samarbeidspartnere som forstår virksomheten, og som hjelper oss med å operere med større presisjon og gjennomslagskraft, sier Richard Åstrand, SVP Digital Strategy Lead i Wallenius Wilhelmsen.– Cognizants kompetanse på våre løsninger i kombinasjon med deres fokus på effektivitet og praktisk teknologiadopsjon,

More news about: Cognizant Technology Solutions


Feb 16, 2026, 03:28 ET Indian Sleep-Science Startup DUSQ (formerly InnerGize) Raises ₹24 Cr to Challenge Global Sleep-Tech Leaders

foundation, we believe it can define the global sleep solutions category."The ₹24 crore seed round also marks a significant moment for Indian med-tech. The global sleep technology market has historically been dominated by U.S. and European players. Institutional backing for a deep-science platform

More news about: DUSQ


Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS

S, Lisnic V, Leone MA. Die Epidemiologie der Myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. Eine Phase-3-Studie mit Inebilizumab bei generalisierter Myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.Europäische Arzneimittelbehörde.

More news about: Amgen


Feb 13, 2026, 15:16 ET Dr. Eric Haeger Scholarship for Future Doctors Announces National Opportunity Supporting Undergraduate Students Pursuing Careers in Medicine

Future Doctors is open to undergraduate students enrolled in accredited colleges or universities who are on a medical career track, including pre-med, health sciences, or closely related disciplines.Applicants are required to submit a thoughtful and well-written essay responding to the following

More news about: Dr. Eric Haeger Scholarship


Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS

Turuspekova S, Lisnic V, Leone MA. Epidemiológia myasténie gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, a kol. Skúšanie fázy 3 inebilizumabu pri generalizovanej myasténii gravis. N Engl J Med. 2025;392(23):2309-2320.Európska agentúra pre lieky. Prvá liečba

More news about: Amgen


Feb 13, 2026, 14:28 ET Caracal Supports HIDA's Med Supply Chain Conference

Healthcare Solutions. "The Med Supply Chain Conference brings the industry together at a critical moment to tackle our biggest challenges, and we're excited to exchange ideas with fellow suppliers and explore the innovations shaping the future of health care."The Med Supply Chain Conference will

More news about: Caracal Products & Services


Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ

Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.Европейское агентство по лекарственным

More news about: Amgen


Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS

Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. (2021) 14 / (1) 7-16 Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. (2025) 392 / (23) 2309-2320Evropská agentura

More news about: Amgen


Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII

myasthenia gravis (Epidemiologia miastenii). J Med Life. 2021;14(1):7-16.Nowak R, Benatar M, Ciafaloni E, et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis (Badanie fazy 3 inebilizumabu w uogólnionej miastenii). N Engl J Med. 2025;392(23):2309-2320.European Medicines

More news about: Amgen


Feb 13, 2026, 02:00 ET EYE PCR erhält CE-Zeichen für fixOflex Endocapsular Device und ermöglicht damit die europäische Markteinführung

https://doi.org/10.2147/OPTH.S358059.Konopińska J, Młynarczyk M, Dmuchowska DA, Obuchowska I. Posterior Capsule Opacification: Ein Überblick über experimentelle Studien. J Clin Med. 2021;10(13):2847. 

More news about: EYE PCR


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.